Another study demonstrated that after the first and second year of HDM immunotherapy, CD63 expression was lower in atopic dermatitis active group than in the atopic dermatitis control group (63), but others did not find a significant change of basophil reactivity to HDM during 24 months of immunotherapy nor a significant association between the change in clinical symptoms and a change in basophil reactivity (64). This evidence concerns the gene CD63 and atopic eczema.